AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2559484 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneously, once daily for 5-9 days)
Number of subjects: 183
Study 2559484 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragmin
Number of subjects: 183
Study 2559484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 206990 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up outreach program
Number of subjects: 0
Study 206990 — intervention group
Group type: COMPARATOR
Intervention: Normal treatment program
Number of subjects: 0
Study 31429811 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron (titrated up to 24 mg daily)
Number of subjects: 400
Study 31429811 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 400
Study 28214385 — intervention group
Group type: EXPERIMENTAL
Intervention: HIGH (6 doses of 250 IU/kg over two weeks)
Number of subjects: 32
Study 28214385 — intervention group
Group type: EXPERIMENTAL
Intervention: COMB (HIGH dose plus nine micro-doses over three weeks)
Number of subjects: 32
Study 28214385 — intervention group
Group type: COMPARATOR
Intervention: HIGH-PLACEBO (saline control for HIGH group)
Number of subjects: 32
Study 28214385 — intervention group
Group type: COMPARATOR
Intervention: COMB-PLACEBO (saline control for COMB group)
Number of subjects: 32
Study 25733628 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal models for month 1
Number of subjects: 0
Study 25733628 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal models for month 2
Number of subjects: 0
Study 25733628 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal models for month 3
Number of subjects: 0
Study 25733628 — intervention group
Group type: COMPARATOR
Intervention: Percent weight loss alone
Number of subjects: 0
Study 23211558 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 0
Study 23211558 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise training
Number of subjects: 0
Study 23211558 — intervention group
Group type: COMPARATOR
Intervention: Detraining period (24 weeks after exercise training)
Number of subjects: 0
Study 22136019 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-pricking therapy combined with rehabilitation
Number of subjects: 96
Study 22136019 — intervention group
Group type: COMPARATOR
Intervention: Blood-pricking therapy
Number of subjects: 96
Study 22136019 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation
Number of subjects: 96
Study 19592054 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (6.4 g/d) for 6 months
Number of subjects: 64
Study 19592054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 17460405 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus ointment applied twice daily for 3 weeks
Number of subjects: 21
Study 17460405 — intervention group
Group type: COMPARATOR
Intervention: 0.12% betamethasone valerate ointment applied twice daily for 3 weeks
Number of subjects: 21
Study 15544076 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue combined with fibrinolysis inhibitor (aprotinin)
Number of subjects: 40
Study 15544076 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fibrin sealant)
Number of subjects: 40
Study 11913478 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg three times daily for 2 months)
Number of subjects: 38
Study 11913478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 9152114 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium bromide (0.15 mg/kg)
Number of subjects: 0
Study 9152114 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium bromide (0.1 mg/kg)
Number of subjects: 0
Study 9152114 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.15 mL/kg)
Number of subjects: 0
Study 7959156 — intervention group
Group type: EXPERIMENTAL
Intervention: sulbactam/ampicillin 0.5/1.0 g, i.v. administered during surgery and repeated 6 hours later
Number of subjects: 100
Study 7959156 — intervention group
Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 100
Study 3610469 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon technique for measuring stoma diameter
Number of subjects: 27
Study 3610469 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon technique for measuring pouch volume
Number of subjects: 27
Study 3610469 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between stoma diameter and weight reduction
Number of subjects: 27
Study 3610469 — intervention group
Group type: EXPERIMENTAL
Intervention: Pouch volume correlation with weight reduction
Number of subjects: 27
Study 30084707 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (63 patients)
Number of subjects: 127
Study 30084707 — intervention group
Group type: EXPERIMENTAL
Intervention: Forzejeh (64 patients)
Number of subjects: 127
Study 30084707 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Metronidazole and Forzejeh
Number of subjects: 127
Study 26571184 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin and crystalloid solutions
Number of subjects: 995
Study 26571184 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid solutions alone
Number of subjects: 995
Study 26571184 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide
Number of subjects: 995
Study 26571184 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T
Number of subjects: 995
Study 26571184 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide and high-sensitivity cardiac troponin T
Number of subjects: 995
Study 25646891 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D regimen of OBV, PTV/r, and DSV
Number of subjects: 0
Study 25646891 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0
Study 25646891 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0
Study 25646891 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol-containing contraceptives
Number of subjects: 0
Study 25646891 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestin-only contraceptive
Number of subjects: 0
Study 25646891 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 of the 20 medications
Number of subjects: 0
Study 25646891 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil, carbamazepine, or ethinyl estradiol-containing contraceptives
Number of subjects: 0
Study 24134424 — intervention group
Group type: EXPERIMENTAL
Intervention: Decellularized dermal skin substitute (DCD) applied after hydrosurgical debridement and covered with negative pressure dressings for 1 week
Number of subjects: 20
Study 24134424 — intervention group
Group type: EXPERIMENTAL
Intervention: Decellularized dermal skin substitute (DCD)
Number of subjects: 20
Study 20090562 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzastaurin plus pemetrexed (250 mg two times per day; 500 mg/m intravenously on day 1 of 21-day cycles)
Number of subjects: 160
Study 20090562 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed (500 mg/m intravenously on day 1 of 21-day cycles)
Number of subjects: 160
Study 20090562 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzastaurin plus pemetrexed (combination arm)
Number of subjects: 160
Study 20090562 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed (pemetrexed arm)
Number of subjects: 160
Study 18381986 — intervention group
Group type: EXPERIMENTAL
Intervention: Random drug testing conducted in school districts
Number of subjects: 1343
Study 18381986 — intervention group
Group type: EXPERIMENTAL
Intervention: Random drug testing for athletes
Number of subjects: 1343
Study 18381986 — intervention group
Group type: EXPERIMENTAL
Intervention: Random drug testing for students in extracurricular activities
Number of subjects: 1343
Study 18381986 — intervention group
Group type: EXPERIMENTAL
Intervention: Random drug testing for all students
Number of subjects: 1343
Study 16380824 — intervention group
Group type: EXPERIMENTAL
Intervention: Trasylol given during surgery
Number of subjects: 40
Study 16380824 — intervention group
Group type: COMPARATOR
Intervention: No specific control intervention mentioned
Number of subjects: 40
Study 15538040 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (TOR) 40 mg for 1 year
Number of subjects: 65
Study 15538040 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 20 mg for 1 year
Number of subjects: 65
Study 15538040 — intervention group
Group type: COMPARATOR
Intervention: Comparison of TOR vs TAM
Number of subjects: 65
Study 11006188 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (Cetrorelix, 0.25 mg daily) during the late follicular phase
Number of subjects: 40
Study 11006188 — intervention group
Group type: COMPARATOR
Intervention: No GnRH agonist or antagonist
Number of subjects: 40
Study 9280175 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet intervention group
Number of subjects: 79
Study 9280175 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific counseling)
Number of subjects: 79
Study 8315554 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg p.o. (oral administration)
Number of subjects: 25
Study 8315554 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mg i.m. (intramuscular administration)
Number of subjects: 25
Study 3450908 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced expectancy (high success potential)
Number of subjects: 96
Study 3450908 — intervention group
Group type: COMPARATOR
Intervention: Control group (no induced expectancy)
Number of subjects: 96
Study 3450908 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor ratings of behavior and attitude
Number of subjects: 96
Study 30138475 — intervention group
Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 49
Study 30138475 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 49
Study 30138475 — intervention group
Group type: EXPERIMENTAL
Intervention: Training-Detraining
Number of subjects: 49
Study 27317711 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope®
Number of subjects: 1100
Study 27317711 — intervention group
Group type: EXPERIMENTAL
Intervention: C-MAC® with D-blade
Number of subjects: 1100
Study 27317711 — intervention group
Group type: EXPERIMENTAL
Intervention: Head and neck position 'supine sniffing' vs 'supine neutral'
Number of subjects: 1100
Study 27317711 — intervention group
Group type: EXPERIMENTAL
Intervention: Otolaryngologic or cardiac surgery vs general surgery
Number of subjects: 1100
Study 27317711 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubation performed by an attending anaesthetist vs a supervised resident
Number of subjects: 1100
Study 27317711 — intervention group
Group type: EXPERIMENTAL
Intervention: Small mouth opening
Number of subjects: 1100
Study 24604819 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 dose of influenza A(H5N1) ISIV in LAIV-experienced subjects
Number of subjects: 0
Study 24604819 — intervention group
Group type: COMPARATOR
Intervention: 2 doses of ISIV in LAIV-naive subjects
Number of subjects: 0
Study 22841321 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation in PEEP/PRVC mode
Number of subjects: 92
Study 22841321 — intervention group
Group type: COMPARATOR
Intervention: Preoperative oxygen supply via face mask or nasal tubes
Number of subjects: 92
Study 20345840 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Behavioral Assessment and Intervention Program (IBAIP)
Number of subjects: 112
Study 20345840 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 112
Study 18487998 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived mononuclear cell therapy
Number of subjects: 3
Study 16182911 — intervention group
Group type: EXPERIMENTAL
Intervention: Lingual flap retraction during mandibular third molar surgery
Number of subjects: 55
Study 16182911 — intervention group
Group type: COMPARATOR
Intervention: No lingual flap retraction during mandibular third molar surgery
Number of subjects: 55
Study 14686230 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir 900 mg once daily
Number of subjects: 364
Study 14686230 — intervention group
Group type: COMPARATOR
Intervention: Oral ganciclovir 1 g three times daily
Number of subjects: 364
Study 9531875 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH with LH (hMG)
Number of subjects: 0
Study 9531875 — intervention group
Group type: COMPARATOR
Intervention: FSH alone
Number of subjects: 0
Study 7787595 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% sucrose
Number of subjects: 60
Study 7787595 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% sucrose
Number of subjects: 60
Study 7787595 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5% sucrose
Number of subjects: 60
Study 7787595 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (control)
Number of subjects: 60
Study 2690926 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% apraclonidine
Number of subjects: 99
Study 2690926 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle of para‐aminoclonidine)
Number of subjects: 99
Study 31295205 — intervention group
Group type: EXPERIMENTAL
Intervention: Home treatment program combined with office-based canalith repositioning procedure (CRP)
Number of subjects: 106
Study 31295205 — intervention group
Group type: COMPARATOR
Intervention: Office-based canalith repositioning procedure (CRP) only
Number of subjects: 106
Study 31295205 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Home treatment + CRP and CRP only)
Number of subjects: 106
Study 28073018 — intervention group
Group type: EXPERIMENTAL
Intervention: Blm helicase
Number of subjects: 0
Study 28073018 — intervention group
Group type: COMPARATOR
Intervention: Improper crossover patterning
Number of subjects: 0
Study 26841526 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive spa and health resort-based treatment with manual therapy
Number of subjects: 110
Study 26841526 — intervention group
Group type: COMPARATOR
Intervention: Balneotherapeutic treatment without manual therapy
Number of subjects: 110
Study 25885729 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml/kg crystalloid infusion (Group I)
Number of subjects: 200
Study 25885729 — intervention group
Group type: COMPARATOR
Intervention: 30 ml/kg crystalloid infusion (Group II)
Number of subjects: 200
Study 25885729 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrual phase
Number of subjects: 200
Study 25885729 — intervention group
Group type: EXPERIMENTAL
Intervention: Proliferative phase
Number of subjects: 200
Study 25885729 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretory phase
Number of subjects: 200
Study 20869038 — intervention group
Group type: EXPERIMENTAL
Intervention: 17‐alpha‐hydroxyprogesterone (17P)
Number of subjects: 69
Study 20869038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 18982439 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (n-3 PUFAs)
Number of subjects: 44
Study 17091128 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (12 mg) + THC (20 mg)
Number of subjects: 43
Study 17091128 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (12 mg) + THC (40 mg)
Number of subjects: 43
Study 17091128 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (12 mg) + THC (2.5 mg)
Number of subjects: 43
Study 17091128 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (12 mg) + THC (10 mg)
Number of subjects: 43
Study 15491089 — intervention group
Group type: EXPERIMENTAL
Intervention: Galloy (gallium based)
Number of subjects: 90
Study 15491089 — intervention group
Group type: COMPARATOR
Intervention: Aristaloy (amalgam based)
Number of subjects: 90
Study 11485281 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropa belladonna tincture (ABT) 5 ml
Number of subjects: 8
Study 11485281 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropa belladonna tincture (ABT) 1 ml
Number of subjects: 8
Study 11485281 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropa belladonna tincture (ABT) 2 ml
Number of subjects: 8
Study 11485281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9771953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin at a dose of 80 mg/m2 on day 1 and etoposide at a dose of 100 mg/m2 on days 1, 2 and 3
Number of subjects: 42
Study 9771953 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 42
Study 8143394 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ofloxacin
Number of subjects: 160
Study 8143394 — intervention group
Group type: COMPARATOR
Intervention: 0.3% tobramycin
Number of subjects: 160
Study 3633356 — intervention group
Group type: EXPERIMENTAL
Intervention: School nursing follow-up services
Number of subjects: 287
Study 3633356 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 287
Study 29495741 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-formant interferers (created using the time-reversed F2 frequency contour, RMS-matched to F2)
Number of subjects: 0
Study 29495741 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferers comprising either one formant (F1) or all three formants (F1, F2, F3)
Number of subjects: 0
Study 29901373 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan dressing
Number of subjects: 20
Study 29901373 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 20
Study 25134034 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief alcohol use disorder treatments
Number of subjects: 89
Study 25134034 — intervention group
Group type: COMPARATOR
Intervention: Change on their own (control group)
Number of subjects: 89
Study 22538671 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drain positioned in the subhepatic space
Number of subjects: 106
Study 22538671 — intervention group
Group type: COMPARATOR
Intervention: Sham drain
Number of subjects: 106
Study 20085614 — intervention group
Group type: EXPERIMENTAL
Intervention: Feldspathic ceramic
Number of subjects: 30
Study 20085614 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS Empress II
Number of subjects: 30
Study 20085614 — intervention group
Group type: COMPARATOR
Intervention: Gradia (laboratory composite)
Number of subjects: 30
Study 17714844 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg D‐amphetamine alone
Number of subjects: 12
Study 17714844 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg riluzole alone
Number of subjects: 12
Study 17714844 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐amphetamine plus riluzole
Number of subjects: 12
Study 17714844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18634926 — intervention group
Group type: EXPERIMENTAL
Intervention: Formocresol (FC)
Number of subjects: 16
Study 18634926 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric sulphate (FS)
Number of subjects: 16
Study 18634926 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (Ca(OH)(2))
Number of subjects: 16
Study 18634926 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 16
Study 15010405 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5% urea-linked gelatin (GEL group)
Number of subjects: 110
Study 15010405 — intervention group
Group type: COMPARATOR
Intervention: 6% hydroxyethyl starch 200/0.5 (HES group)
Number of subjects: 110
Study 10909945 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio computer-assisted self-interviewing (ACASI)
Number of subjects: 2877
Study 9049574 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual withdrawal from benzodiazepines
Number of subjects: 0
Study 9049574 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8449579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 125 mg twice daily for three days
Number of subjects: 163
Study 8449579 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin 100 mg twice daily for three days
Number of subjects: 163
Study 2937337 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 200
Study 2937337 — intervention group
Group type: COMPARATOR
Intervention: Diazemuls
Number of subjects: 200
Study 31967673 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (8 mg/kg) and Everolimus (4 mg/m2)
Number of subjects: 15
Study 31967673 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg) and Everolimus (4 mg/m2)
Number of subjects: 15
Study 31967673 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab and Everolimus
Number of subjects: 15
Study 30657852 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 weeks trastuzumab
Number of subjects: 866
Study 30657852 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 year trastuzumab
Number of subjects: 866
Study 30657852 — intervention group
Group type: COMPARATOR
Intervention: TILs <20%
Number of subjects: 866
Study 30657852 — intervention group
Group type: COMPARATOR
Intervention: TILs ≥20%
Number of subjects: 866
Study 30657852 — intervention group
Group type: COMPARATOR
Intervention: Comparison of short vs long arm for TILs <20%
Number of subjects: 866
Study 30657852 — intervention group
Group type: COMPARATOR
Intervention: Comparison of short vs long arm for TILs ≥20%
Number of subjects: 866
Study 28081369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol cookstove intervention
Number of subjects: 324
Study 28081369 — intervention group
Group type: COMPARATOR
Intervention: Control (kerosene or firewood)
Number of subjects: 324
Study 28081369 — intervention group
Group type: COMPARATOR
Intervention: Control (kerosene)
Number of subjects: 324
Study 25842470 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosmetic topical slimming treatment
Number of subjects: 110
Study 25842470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 23976883 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium dichloroisocyanurate (NaDCC) tablets distributed during bi-monthly household visits; intervention included an intensive promotion campaign.
Number of subjects: 2986
Study 23976883 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 2986
Study 23976883 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium dichloroisocyanurate (NaDCC) tablets intervention.
Number of subjects: 2986
Study 21896611 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 111